BioSpace News Archive

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,590,209, titled “Use of Bremelanotide in Patients with Controlled Hypertension.”

Enveric Biosciences announced today the appointment of Kevin Coveney, CPA, to the position of Chief Financial Officer.

Korro Bio, Inc ., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Steve Colletti, Ph.D. as Chief Scientific Officer.

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics® today announced significant progress updates for its two lead clinical development programs.

Tevard Biosciences , Inc., the pioneer of tRNA-based therapies for severe genetic diseases, today announced a four-year global research collaboration with Vertex Pharmaceuticals Incorporated aimed at creating new tRNA-based therapies for patients with Duchenne muscular dystrophy (DMD).

Cabaletta Bio, Inc. announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:10 p.m. ET in Boston, MA.

Amarin Corporation plc (NASDAQ:AMRN) and CSL Seqirus today announced that the two companies have entered into an exclusive license and distribution agreement under which Amarin will license exclusive rights to VAZKEPA to CSL Seqirus to secure pricing and reimbursement and commercialize the product across Australia and New Zealand.

Turn Biotechnologies today will present data showing that its ERA™ technology can be used to dramatically improve T cells’ ability to fight cancer.

Factor Bioscience Inc. announced the results of preclinical testing of aerosolized mRNA formulations currently under development for the treatment of pneumonia-associated lung inflammation.

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2022, and recent company developments.